Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa (Phase 1/Phase 2a), Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)

NCT03066258 is registered in ClinicalTrials.gov with REGENXBIO Inc. as lead sponsor.

NCT NCT03066258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03066258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa (Phase 1/Phase 2a), Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)
Lead sponsor
REGENXBIO Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 29, 2017
Completion date
June 17, 2021
Enrollment
42 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration, wet age-related macular degeneration